Learning Objectives

At the completion of the meeting, attendees should be able to:

  •   

    1.      Understand current understanding of the biology, biochemistry and genetics of MDS including role of
             the microenvironment and molecular testing

    2.      Describe the role of transfusion and optimization of blood product use in MDS

    3.      Gain insight into the evolution of classification & new prognostic systems in MDS

    4.      Evaluate the role of iron in MDS disease progression and management of iron overload in the disease.

    5.      Review pathophysiology and treatment of MDS overlap syndromes

    6.      Review current understanding of the role of paroxysmal nocturnal hemoglobinuria disease clones
              in MDS pathophysiology and management

    7.      Update treatment strategies in MDS including use of novel agents

    8.      Review the role of intensive therapies and stem cell transplantation in MDS

    9.      Discuss how MDS affects patient frailty and quality of life, and the importance of this focus in MDS care

    10.  Discuss a Canadian perspective on MDS landscape & treatment

    11.  Facilitate potential for collaborative research projects to advance the field of MDS care.